Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28475499 | 0.89 | CHRM1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL11633541 | 0.85 | CA2 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL10412071 | 0.84 | CHRM1 (0.70) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL321082 | 0.84 | CA2 (0.65) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1554383 | 0.81 | CA2 (0.68) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL2839819 | 0.81 | FOLH1 (0.67) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7776230 | 0.81 | GRIK1 (0.58) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL6120281 | 0.81 | GRIK1 (0.58) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL22534499 | 0.81 | GRIK1 (0.58) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL10562619 | 0.81 | GRIK1 (0.58) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110041309-B | 2-carboxypiperazine-linked tacrine-8-amino (hydroxy) quinoline derivative and preparation and application thereof | 广东工业大学 | 2022-01-28 | — | — | CN | claimed |
| CN-117741025-A | Method for detecting impurities in ethyl 2,3-dibromopropionate | 石家庄四药有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11623943-B2 | Method for producing lacosamide and intermediate thereof | API CORPORATION (JP) | 2023-04-11 | — | — | US | disclosed |
| CN-110041309-B | 2-carboxypiperazine-linked tacrine-8-amino (hydroxy) quinoline derivative and preparation and application thereof | 广东工业大学 | 2022-01-28 | — | — | CN | disclosed |
| US-20210188904-A1 | METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF | API CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-10975117-B2 | Method for producing lacosamide and intermediate thereof | API CORPORATION (JP) | 2021-04-13 | — | — | US | disclosed |
| EP-3659997-A1 | METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF | API Corporation (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20180371013-A1 | METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF | API CORPORATION (JP) | 2018-12-27 | — | — | US | disclosed |
| EP-3375771-A1 | METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF | API Corporation (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-1796657-B1 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623943-B2 | Method for producing lacosamide and intermediate thereof | CA3, TREH, NAAA | CHRM1 3966/4885AKR1A1 1159/4885CHRM3 3104/4885 |
| US-20210188904-A1 | METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF | CA3, TREH, NAAA | CHRM1 3966/4885AKR1A1 1159/4885CHRM3 3104/4885 |
| US-10975117-B2 | Method for producing lacosamide and intermediate thereof | CA3, TREH, NAAA | CHRM1 3966/4885AKR1A1 1159/4885CHRM3 3104/4885 |
| US-20180371013-A1 | METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF | CA3, TREH, NAAA | CHRM1 3966/4885AKR1A1 1159/4885CHRM3 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.